Ana Catalina Tantu

Dr. Ana Catalina Tantu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2025 in Pathogens
Verified
Journal Article
Open access
Adelina-Gabriela NiculescuAdelina-Gabriela Niculescu
Adelina-Gabriela Niculescu
MMMihaela Magdalena Mitache
Mihaela Magdalena Mitache
Alexandru Mihai GrumezescuAlexandru Mihai Grumezescu
Alexandru Mihai Grumezescu
Carmen ChifiriucCarmen Chifiriuc
Carmen Chifiriuc
Mara MihaiMara Mihai
Mara Mihai
Corneliu Ovidiu VrancianuCorneliu Ovidiu Vrancianu
Corneliu Ovidiu Vrancianu
Antibiotic resistance represents a growing public health threat, with airborne drug-resistant strains being especially alarming due to their ease of transmission and association with severe respiratory infections. The respiratory microbiome plays a pivotal role in maintaining respiratory health, influencing the dynamics of antibiotic resistance among airborne pathogenic microorganisms. In this context, this review proposes the exploration of the complex interplay between the respiratory microbiota and antimicrobial resistance, highlighting the implications of microbiome diversity in health and disease. Moreover, strategies to mitigate antibiotic resistance, including stewardship programs, alternatives to traditional antibiotics, probiotics, microbiota restoration techniques, and nanotechnology-based therapeutic interventions, are critically presented, setting an updated framework of current management options. Therefore, through a better understanding of respiratory microbiome roles in antibiotic resistance, alongside emerging therapeutic strategies, this paper aims to shed light on how the global health challenges posed by multi-drug-resistant pathogens can be addressed.
1

11 June 2026 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
ATAna Catalina Tantu
Ana Catalina Tantu
TMTANTU MARILENA MONICA
TANTU MARILENA MONICA
Corneliu Ovidiu VrancianuCorneliu Ovidiu Vrancianu
Corneliu Ovidiu Vrancianu
ASAndreea-Mihaela Sandu
Andreea-Mihaela Sandu
RCRoxana- Elena Cristian
Roxana- Elena Cristian
IVIonica Daniel Vilcea
Ionica Daniel Vilcea
Burn injuries are associated with significant morbidity and mortality, largely driven by infectious complications. Disruption of the skin barrier, systemic inflammation, and postburn immunosuppression promote microbial colonization and progression to local and systemic infections, a challenge further exacerbated by the increasing prevalence of multidrug-resistant organisms (MDRO). Patients with extensive burns, inhalation injury, prolonged hospitalization, and invasive device use are particularly vulnerable. The microbiological profile of burn wound infections evolves dynamically, shifting from early Gram-positive predominance to Gram-negative and multidrug-resistant (MDR) pathogens, including members of the ESKAPE group, in later stages. Effective management, therefore, requires an integrated approach combining early surgical intervention, strict infection control measures, continuous microbiological surveillance, and targeted antimicrobial therapy. This narrative review synthesizes current evidence on the pathophysiology, risk factors, and microbiological dynamics of burn-associated infections, alongside contemporary prevention and treatment strategies, including topical therapies, advanced biomaterials, systemic antibiotic approaches, and antimicrobial stewardship. Emerging strategies such as nanoparticle-based systems and artificial intelligence-driven predictive models highlight a shift toward precision medicine in burn care; however, their clinical translation remains limited by insufficient validation and standardization. In conclusion, optimizing outcomes in burn-associated infections will depend on integrating evidence-based clinical practices with innovative technologies, while reinforcing antimicrobial stewardship and developing validated predictive tools to address the growing burden of antimicrobial resistance.

20 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
PAPAUNESCU ALINA
PAUNESCU ALINA
NSNicoleta Anca Sutan
Nicoleta Anca Sutan
TMTANTU MARILENA MONICA
TANTU MARILENA MONICA
Ponepal Maria CristinaPonepal Maria Cristina
Ponepal Maria Cristina
CSCristina Liliana Soare
Cristina Liliana Soare
CPCatalina Gabriela Pisoschi
Catalina Gabriela Pisoschi
Introduction: The clinical implementation of noninvasive tests for liver fibrosis assessment has attracted increasing attention, particularly for diagnosing advanced fibrosis (≥F3). This observational study aimed to evaluate the stratification accuracy of nine direct and seven indirect biomarkers across four etiologies: chronic hepatitis B (CHB), chronic hepatitis C (CHC), alcoholic liver cirrhosis (ALC), and nonalcoholic liver cirrhosis (NALC). Materials and Methods: Our study was conducted on 116 participants, including 96 with chronic liver disease (16 CHB, 15 CHC, 49 ALC, and 16 NALC) and 20 healthy controls. The values of direct (aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum albumin, platelet count, international normalized ratio, gamma-glutamyl transpeptidase, CD5 antigen-like, and transforming growth factor-beta 1) and indirect non-serological biomarkers (De Ritis ratio, albumin–bilirubin score, gamma-glutamyl transpeptidase-to-platelet ratio, aspartate aminotransferase-to-platelet-ratio index, fibrosis-4 index, INR-to-platelet ratio, and fibrosis quotient) were analyzed for their discriminative power in fibrosis stratification. Results: Statistical analyses revealed a significant correlation (0.05 level; two-tailed), and AUC 95% CI ranged within 0.50–1.00 between the direct and indirect biomarker values across all etiologies. Among the evaluated biomarkers, the recorded AUC was 0.998 in CHB for APRI, 0.981 in CHC for FIB-4, and 1.000 in ALC and NALC for APRI and AST, respectively, while CD5L consistently achieved an AUC of 1.000 across all etiologies. Conclusions: These findings suggest that applying a multifactorial approach in liver pathology may improve diagnosis accuracy compared to the use of individual biomarkers and can provide data that may inform the development of clinically applicable mathematical models.

7 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PAPAUNESCU ALINA
PAUNESCU ALINA
NSNicoleta Anca Sutan
Nicoleta Anca Sutan
D(Diana-Ionela Popescu (Stegarus)
Diana-Ionela Popescu (Stegarus)
CSCristina Liliana Soare
Cristina Liliana Soare
Ponepal Maria CristinaPonepal Maria Cristina
Ponepal Maria Cristina
TMTANTU MARILENA MONICA
TANTU MARILENA MONICA
Objective: To analyze demographic traits, clinical complications, and healthcare use in patients with chronic liver disease across major etiologies in a large Romanian cohort. Methods: A retrospective study (2019–2023) of 2359 patients with chronic hepatitis C (CHC), hepatitis associated with alcohol (ALH), cirrhosis associated with alcohol (ALC), or non-alcoholic cirrhosis (NALC). Data on demographics, clinical outcomes, and hospitalizations were analyzed using descriptive statistics, regression modeling, and clustering in IBM SPSS 27.0.1. Results: CHC patients were oldest (mean 67.5 ± 12.3 years), while ALH patients were youngest (56.0 ± 11.0 years). CHC prevalence increased with age (10.0% in ≤30-year-olds to 87.1% in ≥81-year-olds; γ = 0.535, p < 0.001). Females comprised 60–70% of CHC cases, males > 85% of ALH and >78% of ALC. Mean hospitalization duration decreased from 13.80 days (2019) to 9.10 days (2023), yet cirrhotic patients had the longest stays (NALC: 16.37 ± 14.34; ALC: 17.66 ± 12.96) versus CHC (10.38 ± 10.14). Etiology was the strongest predictor of hospitalization length. Portal hypertension (PH) was the most common complication (54.3%), with males bearing more severe hepatic complications (ascites—38.3%; PH—66.8%). Conclusions: Hospital-based Romanian cohort analysis revealed that patient presentation and outcomes are fundamentally shaped by the interplay of etiology, sex, and age. We found a distinct female predominance in CHC, a pronounced male predominance in alcohol-related diseases, and evolving trends in non-alcoholic cirrhosis. These determinants dictate specific epidemiological patterns, hospitalization burdens, and complication risks, underscoring the critical need for a paradigm shift toward personalized, etiology-driven, and sex-tailored clinical management.

8 May 2026 in Diseases
Verified
Journal Article
Open access
PDF file
PAPAUNESCU ALINA
PAUNESCU ALINA
NSNicoleta Anca Sutan
Nicoleta Anca Sutan
CSCristina Liliana Soare
Cristina Liliana Soare
Ponepal Maria CristinaPonepal Maria Cristina
Ponepal Maria Cristina
ATAna Catalina Tantu
Ana Catalina Tantu
CPCatalina Gabriela Pisoschi
Catalina Gabriela Pisoschi
Background: Chronic hepatitis B and C remain major causes of progressive liver disease, while HBV–HCV coinfection is associated with accelerated fibrosis and hepatocellular injury. Methods: This study evaluated integrated biochemical, histopathological, and immunohistochemical features in patients with chronic hepatitis B (CHB, n = 29), chronic hepatitis C (CHC, n = 15), and CHB+C coinfection (CHB+C, n = 10). Liver biopsies were assessed using Ishak and METAVIR scoring systems, alongside immunohistochemical analysis of α-smooth muscle actin (α-SMA), transforming growth factor-β1 (TGF-β1), CD5L, and glial fibrillary acidic protein (GFAP), quantified by H-score. These findings were correlated with biochemical, hematological, and prognostic parameters. Results: Coinfected patients exhibited significantly higher serum ALT, AST, and GGT levels (p ≤ 0.011) and increased CD5L expression (median H-score 197.5 vs. 135 in CHB, p = 0.009), indicating enhanced macrophage-associated inflammatory activity. Although fibrosis stages were comparable across groups, median H-scores for α-SMA, TGF-β1, and GFAP showed a consistent upward trend in CHB+C, suggesting intensified profibrogenic signaling. Principal Component Analysis identified distinct biochemical clusters related to hepatocellular injury, hepatic functional impairment (synthetic and excretory axis), and lipid metabolism. Conclusions: These findings highlight a multidimensional pattern of liver injury in chronic viral hepatitis, with CHB+C coinfection amplifying profibrogenic and hepatocellular markers, both biochemically and histologically.

8 December 2025 in Romanian Journal of Morphology and Embryology
Verified
Journal Article
Open access
GPGeorge Popescu
George Popescu
MZMarius-Cristian Zaharia
Marius-Cristian Zaharia
DSDenisa Soci
Denisa Soci
CACarla-Maria Andrasi
Carla-Maria Andrasi
ANAngela Neacşu
Angela Neacşu
GIGeorgeta Ionescu
Georgeta Ionescu
Extradural arachnoid cysts (EACs) are rare, fluid-filled lesions located outside the dura mater, predominantly found in the thoracic spine. While many remain asymptomatic, their progressive enlargement may lead to significant neurological deficits due to spinal cord compression. This case report describes a 43-year-old patient presenting with incomplete paraplegia (Frankel grade C) due to a thoracic EAC at the T5–T6 level. Surgical management involved laminectomy, complete cyst excision, and dural defect repair, leading to neurological improvement. The discussion reviews current diagnostic and therapeutic approaches, emphasizing the importance of early intervention to optimize patient outcomes.